Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology

New Meds to Reduce Beta-Thalassemia Transfusions?

At a Glance

Adults with transfusion-dependent beta-thalassemia may reduce their blood transfusion needs using luspatercept (Reblozyl), an FDA-approved injection given every three weeks. Additionally, daily oral medications like mitapivat are currently in promising late-stage clinical trials.

In this answer

2 sections

01

FDA-Approved Option: Luspatercept (Reblozyl)

02

Medications in Clinical Trials: Pyruvate Kinase Activators

Yes, there are new, non-curative medications available and in development that can help reduce the number of blood transfusions you need. For adults with beta-thalassemia major who cannot or prefer not to undergo curative therapies like stem cell transplants or gene therapy, the FDA has approved a medication called luspatercept (brand name Reblozyl) [1][2]. Additionally, there are promising oral medications currently in clinical trials, such as mitapivat, that aim to further reduce your transfusion burden [3][4].

FDA-Approved Option: Luspatercept (Reblozyl)

Luspatercept is an FDA-approved injectable medication designed specifically for adults with transfusion-dependent beta-thalassemia [1]. It is used alongside your normal blood transfusions and standard iron chelation therapy, with the goal of reducing how much blood you need over time. It works by targeting the underlying problem in beta-thalassemia: ineffective erythropoiesis (the body’s inability to fully develop red blood cells).

  • How it works: Luspatercept binds to certain proteins (TGF-β superfamily ligands) that normally block red blood cells from fully maturing [5][6]. By blocking these proteins, it allows your red blood cells to successfully complete their development [7][8].
  • How it is given: The medication is given as a subcutaneous injection (a shot just under the skin) by a healthcare provider once every 3 weeks [9][10]. Your doctor will calculate your dose based on your body weight (typically starting at 1.0 mg/kg) [10]. Note: Because this is a newer specialty medication, it can be expensive and often requires insurance approval. Your doctor’s office or the drug manufacturer may offer patient support programs to help navigate this process.
  • Effectiveness and timeline: In a major clinical trial (the BELIEVE trial), luspatercept significantly reduced the number of blood transfusions patients needed [11][12]. Over the long term, more than half of the patients on the medication achieved at least a 33% reduction in their transfusion burden [13]. Patients also experienced significant decreases in their serum ferritin levels (a measure of iron buildup in the body) [14]. It is important to know that results are not immediate; clinical trials measured success by looking at reductions over several months (typically evaluated around weeks 13 through 24 of treatment) [11][15].
  • Side effects: While generally well-tolerated, some patients experience temporary side effects like bone pain, joint pain (arthralgia), dizziness, high blood pressure, and high uric acid levels [16]. Your doctor will monitor your blood pressure, kidney function, and hemoglobin levels regularly [17][18].

Medications in Clinical Trials: Pyruvate Kinase Activators

Beyond luspatercept, researchers are investigating new daily oral pills called pyruvate kinase (PK) activators. The most prominent of these is mitapivat.

  • How it works: Mitapivat activates an enzyme in your red blood cells called pyruvate kinase, which helps the cells produce more energy (ATP) [19][20]. This extra energy helps the red blood cells survive longer and reduces hemolysis (the premature destruction of red blood cells) [21][22].
  • Clinical trial status: Mitapivat is currently being studied in Phase 3 clinical trials (like the ENERGIZE-T trial) for adults with transfusion-dependent beta-thalassemia [3][23]. Another similar drug, etavopivat, is also in late-stage development [16].
  • Potential benefits: Because these medications are taken orally as a pill rather than injected, they could offer a more convenient way to decrease your transfusion needs and improve hemoglobin levels if they receive FDA approval [23][4]. They have been generally well-tolerated in trials so far [24].

Common questions in this guide

How does luspatercept (Reblozyl) work for beta-thalassemia?
Luspatercept works by blocking certain proteins that normally stop red blood cells from fully maturing. By doing this, it allows your red blood cells to complete their development, which helps reduce the number of blood transfusions you need over time.
How is luspatercept administered?
The medication is given as a subcutaneous injection, which is a shot just under the skin. It is administered by a healthcare provider once every three weeks, with the dose calculated based on your body weight.
How long does it take for luspatercept to reduce my transfusion needs?
Results are not immediate. It typically takes several months of treatment, often evaluated around 13 to 24 weeks, for your doctor to determine if the medication is successfully reducing your need for blood transfusions.
What are the side effects of luspatercept injections?
Common temporary side effects can include bone pain, joint pain (arthralgia), dizziness, high blood pressure, and high uric acid levels. Your healthcare team will regularly monitor your blood pressure, kidney function, and hemoglobin levels during treatment.
Are there oral medications available to reduce blood transfusions?
While currently only injections are FDA-approved, researchers are studying daily oral pills called pyruvate kinase activators, such as mitapivat. These medications are in late-stage clinical trials and may offer a more convenient option if approved in the future.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a good candidate for luspatercept (Reblozyl), given my current transfusion schedule, spleen status, and overall health history?
  2. 2.If I start an injection like luspatercept, realistically how many months will we wait to evaluate if it is effectively reducing my transfusion needs?
  3. 3.Should I expect my current iron chelation therapy to change if my transfusion burden and ferritin levels start to decrease?
  4. 4.Are there any clinical trials for oral medications like mitapivat happening at or near this clinic that I might be eligible to join?
  5. 5.Can your office help me navigate the insurance approval process or find patient assistance programs for these newer specialty medications?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does Beta-Thalassemia Major Affect Growth & Puberty?Does Beta-Thalassemia Gene Therapy Cause Infertility?Why Does Beta-Thalassemia Cause Bone & Facial Changes?How Do Zynteglo & Casgevy Work for Beta-Thalassemia?How to Manage Teen Beta-Thalassemia Treatment BurnoutChances of Beta-Thalassemia Major for Carrier ParentsWhat Happens If You Miss Iron Chelation Doses?What Is a Cardiac T2* MRI for Thalassemia?How Much Do Zynteglo and Casgevy Gene Therapies Cost?What Is the Life Expectancy for Beta-Thalassemia Major?What is the Pesaro Score for Stem Cell Transplants?Why Do You Need Vision & Hearing Exams With Chelation?Why Do Beta-Thalassemia Symptoms Start at 3-6 Months?Why is Spleen Removal Needed for Beta-Thalassemia?

References

References (24)
  1. 1

    Luspatercept for β-thalassemia: beyond red blood cell transfusions.

    Taher AT, Cappellini MD

    Expert opinion on biological therapy 2021; (21(11)):1363-1371 doi:10.1080/14712598.2021.1968825.

    PMID: 34404288
  2. 2

    Innovative Treatments for Rare Anemias.

    Cappellini MD, Marcon A, Fattizzo B, Motta I

    HemaSphere 2021; (5(6)):e576 doi:10.1097/HS9.0000000000000576.

    PMID: 34095760
  3. 3

    Pyruvate kinase activators: targeting red cell metabolism in thalassemia.

    Kuo KHM

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):114-120 doi:10.1182/hematology.2023000468.

    PMID: 38066911
  4. 4

    Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review.

    Ahmed SH, Qadar LT, Ahmed J, et al.

    Expert review of hematology 2025; (18(8)):633-648 doi:10.1080/17474086.2025.2522295.

    PMID: 40526104
  5. 5

    New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.

    Tefferi A

    American journal of hematology 2021; (96(7)):761-763 doi:10.1002/ajh.26197.

    PMID: 33861878
  6. 6

    Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice.

    Weidner H, Wobus M, Hofbauer LC, et al.

    Leukemia 2022; (36(11)):2715-2718 doi:10.1038/s41375-022-01702-1.

    PMID: 36175549
  7. 7

    Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis.

    Mukherjee S, Brown-Bickerstaff C, Falkenstein A, et al.

    HemaSphere 2024; (8(1)):e38 doi:10.1002/hem3.38.

    PMID: 38434524
  8. 8

    Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.

    Martinez PA, Li R, Ramanathan HN, et al.

    Journal of cellular and molecular medicine 2020; (24(11)):6162-6177 doi:10.1111/jcmm.15243.

    PMID: 32351032
  9. 9

    Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.

    Kang C, Syed YY

    Drugs 2021; (81(8)):945-952 doi:10.1007/s40265-021-01527-9.

    PMID: 33970460
  10. 10

    Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.

    Chen N, Kassir N, Laadem A, et al.

    Journal of clinical pharmacology 2021; (61(1)):52-63 doi:10.1002/jcph.1696.

    PMID: 32696522
  11. 11

    A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

    Cappellini MD, Viprakasit V, Taher AT, et al.

    The New England journal of medicine 2020; (382(13)):1219-1231 doi:10.1056/NEJMoa1910182.

    PMID: 32212518
  12. 12

    Luspatercept: First Approval.

    Markham A

    Drugs 2020; (80(1)):85-90 doi:10.1007/s40265-019-01251-5.

    PMID: 31939073
  13. 13

    Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.

    Cappellini MD, Viprakasit V, Georgiev P, et al.

    The Lancet. Haematology 2025; (12(3)):e180-e189 doi:10.1016/S2352-3026(24)00376-4.

    PMID: 39947215
  14. 14

    Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.

    Garbowski MW, Ugidos M, Risueño A, et al.

    American journal of hematology 2024; (99(2)):182-192 doi:10.1002/ajh.27102.

    PMID: 37782758
  15. 15

    The use of luspatercept for thalassemia in adults.

    Cappellini MD, Taher AT

    Blood advances 2021; (5(1)):326-333 doi:10.1182/bloodadvances.2020002725.

    PMID: 33570654
  16. 16

    Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review.

    Dighriri IM, Alrabghi KK, Sulaiman DM, et al.

    Cureus 2022; (14(11)):e31570 doi:10.7759/cureus.31570.

    PMID: 36540460
  17. 17

    Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia.

    Sheth S, Taher AT, Coates TD, et al.

    British journal of haematology 2023; (201(5)):824-831 doi:10.1111/bjh.18801.

    PMID: 37037668
  18. 18

    Mesangial sclerosing glomerulopathy following luspatercept treatment - a case report.

    Bataille S, Daniel L, Torrents J, et al.

    BMC nephrology 2026; (27(1)).

    PMID: 41668029
  19. 19

    AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

    Kung C, Hixon J, Kosinski PA, et al.

    Blood 2017; (130(11)):1347-1356 doi:10.1182/blood-2016-11-753525.

    PMID: 28760888
  20. 20

    Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.

    De SK

    Current medicinal chemistry 2024; (31(6)):683-687 doi:10.2174/0929867330666230430002709.

    PMID: 37125655
  21. 21

    The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.

    Matte A, Federti E, Kung C, et al.

    The Journal of clinical investigation 2021; (131(10)).

    PMID: 33822774
  22. 22

    The ENERGIZE trial: Is mitapivat ready to take center stage in NTDT management?

    Algeri M, Locatelli F

    Med (New York, N.Y.) 2025; (6(9)):100844 doi:10.1016/j.medj.2025.100844.

    PMID: 40945502
  23. 23

    Efficacy and Safety of Mitapivat in Pyruvate Kinase Deficiency: A Systematic Review and Meta-analysis of Clinical Trials.

    Mohammed HE, Bady Z, Farhat YZ, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2025; (41(1)):112-120 doi:10.1007/s12288-024-01830-x.

    PMID: 39917491
  24. 24

    Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study.

    Kuo KHM, Layton DM, Lal A, et al.

    British journal of haematology 2025; (206(6)):1764-1773 doi:10.1111/bjh.20058.

    PMID: 40394935

This page explains new medication options for beta-thalassemia for educational purposes. Your hematologist is the best source for determining if these treatments are right for your specific transfusion needs.

Get notified when new evidence is published on Beta-thalassemia major.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.